{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-07-11T11:58:03.076387+00:00","company":{"ticker":"TPST","cik":1544227,"company_name":"Tempest Therapeutics, Inc."},"pagination":{"limit":100,"returned":55,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","counterparties":{"contract_counterparty":[{"display_name":"Institutional Investors and Factor Bioscience Inc.","detail":"equity_purchase","count":2,"first_seen":"2026-03-23T23:59:59+00:00","last_seen":"2026-03-23T23:59:59+00:00","evidence_fact_ids":[27728,27729]},{"display_name":"Computershare Trust Company, N.A.","detail":"other","count":1,"first_seen":"2023-10-11T23:59:59+00:00","last_seen":"2023-10-11T23:59:59+00:00","evidence_fact_ids":[107336]},{"display_name":"Oxford Finance LLC, as collateral agent, and certain additional lenders","detail":"credit_facility","count":1,"first_seen":"2022-12-29T23:59:59+00:00","last_seen":"2022-12-29T23:59:59+00:00","evidence_fact_ids":[188576]},{"display_name":"a holder of certain existing warrants to purchase shares of the Company’s common stock","detail":"equity_purchase","count":1,"first_seen":"2026-06-01T23:13:20+00:00","last_seen":"2026-06-01T23:13:20+00:00","evidence_fact_ids":[51085]}],"ma_counterparty":[{"display_name":"Erigen LLC","detail":"acquisition","count":1,"first_seen":"2026-02-06T23:59:59+00:00","last_seen":"2026-02-06T23:59:59+00:00","evidence_fact_ids":[24892]}]},"facts":[{"fact_type":"executive_change","fact_key":"e43b294a90","cik":1544227,"ticker":"TPST","company_name":"Tempest Therapeutics, Inc.","filed_at":"2026-06-04T21:00:25+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2026-06-04","interim":false,"role":"Class II Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"William Drake Richey was appointed as Class II Director at Tempest Therapeutics, Inc..","evidence_excerpt":"the Board appointed Dr. John David Yee and Mr. William Drake Richey as Class II directors to fill vacancies on the Board.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-26-257684","anchor_url":"https://secwatch.observer/filing/0001193125-26-257684#claim-e43b294a90","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1544227/000119312526257684/0001193125-26-257684-index.htm"},{"fact_type":"executive_change","fact_key":"2b3fdc8275","cik":1544227,"ticker":"TPST","company_name":"Tempest Therapeutics, Inc.","filed_at":"2026-06-04T21:00:25+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2026-06-04","interim":false,"role":"Class II Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"John David Yee was appointed as Class II Director at Tempest Therapeutics, Inc..","evidence_excerpt":"the Board appointed Dr. John David Yee and Mr. William Drake Richey as Class II directors to fill vacancies on the Board.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-26-257684","anchor_url":"https://secwatch.observer/filing/0001193125-26-257684#claim-2b3fdc8275","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1544227/000119312526257684/0001193125-26-257684-index.htm"},{"fact_type":"executive_change","fact_key":"7c3c05419e","cik":1544227,"ticker":"TPST","company_name":"Tempest Therapeutics, Inc.","filed_at":"2026-06-04T21:00:25+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2026-06-05","interim":false,"role":"Vice President, Finance, Principal Financial Officer and Corporate Secretary","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Justin Trojanowski was appointed as Vice President, Finance, Principal Financial Officer and Corporate Secretary at Tempest Therapeutics, Inc..","evidence_excerpt":"the Board of Directors of the Company (the “Board”) appointed Mr. Justin Trojanowski as Vice President, Finance, Principal Financial Officer and Corporate Secretary of the Company, in addition to his current role as Corporate Controller, Treasurer and Principal Accounting Officer of the Company.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-26-257684","anchor_url":"https://secwatch.observer/filing/0001193125-26-257684#claim-7c3c05419e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1544227/000119312526257684/0001193125-26-257684-index.htm"},{"fact_type":"executive_change","fact_key":"f97c7ac986","cik":1544227,"ticker":"TPST","company_name":"Tempest Therapeutics, Inc.","filed_at":"2026-06-04T21:00:25+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2026-06-05","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":"Justin Trojanowski","successor_named":true},"claim":"Nicholas Maestas resigned as Chief Financial Officer at Tempest Therapeutics, Inc..","evidence_excerpt":"Mr. Nicholas Maestas notified Tempest Therapeutics, Inc. (the “Company”) of his decision to resign from his position as Chief Financial Officer of the Company and from any and all other positions he holds with the Company, effective as of June 5, 2026.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-26-257684","anchor_url":"https://secwatch.observer/filing/0001193125-26-257684#claim-f97c7ac986","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1544227/000119312526257684/0001193125-26-257684-index.htm"},{"fact_type":"equity_issuance","fact_key":"650f82dab9a115cbef5152bbeb6721aad82a476f","cik":1544227,"ticker":"TPST","company_name":"Tempest Therapeutics, Inc.","filed_at":"2026-06-01T23:13:20+00:00","payload":{"action":"warrant_issuance","consideration_text":"cash exercise of 1,172,414 shares at $1.73 per share, aggregate gross proceeds approx $2.0 million","effective_date":"2026-05-28","item_codes_triggered":["3.02"],"purchaser":"holder of existing warrants","security_type":"warrant","shares_text":"2,344,828 shares"},"claim":"Tempest Therapeutics, Inc. issued 2,344,828 shares of warrant to holder of existing warrants for cash exercise of 1,172,414 shares at $1.73 per share, aggregate gross proceeds approx $2.0 million.","evidence_excerpt":"Pursuant to the Inducement Letter, the holder agreed to exercise for cash the Existing Warrants to purchase an aggregate of 1,172,414 shares of the Company’s common stock at a reduced exercise price of $1.73 per share in consideration of the Company’s agreement to issue to the holder a new unregistered common stock purchase warrant (the “ New Warrant ”) to purchase up to 2,344,828 shares of common stock.","confidence":0.99,"filing_url":"https://secwatch.observer/filing/0001193125-26-251994","anchor_url":"https://secwatch.observer/filing/0001193125-26-251994#claim-650f82dab9a115cbef5152bbeb6721aad82a476f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1544227/000119312526251994/0001193125-26-251994-index.htm"},{"fact_type":"material_agreement","fact_key":"ab9d3c4d86668ce04a6c3c371ad4e715e0876cef","cik":1544227,"ticker":"TPST","company_name":"Tempest Therapeutics, Inc.","filed_at":"2026-06-01T23:13:20+00:00","payload":{"action":"entry","agreement_name":"Inducement Letter","agreement_type":"equity_purchase","counterparty":"a holder of certain existing warrants to purchase shares of the Company’s common stock","effective_date":"2026-05-28","item_codes_triggered":["1.01"],"value_text":"approximately $2.0 million"},"claim":"Tempest Therapeutics, Inc. entered into Inducement Letter with a holder of certain existing warrants to purchase shares of the Company’s common stock valued at approximately $2.0 million (effective 2026-05-28).","evidence_excerpt":"On May 28, 2026, Tempest Therapeutics, Inc., a Delaware corporation (the “ Company ”), entered into a warrant exercise and inducement offer letter agreement (the “ Inducement Letter ”) with a holder of certain existing warrants to purchase shares of the Company’s common stock","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-251994","anchor_url":"https://secwatch.observer/filing/0001193125-26-251994#claim-ab9d3c4d86668ce04a6c3c371ad4e715e0876cef","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1544227/000119312526251994/0001193125-26-251994-index.htm"},{"fact_type":"executive_change","fact_key":"561bc49325","cik":1544227,"ticker":"TPST","company_name":"Tempest Therapeutics, Inc.","filed_at":"2026-05-29T21:01:10+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2026-05-23","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Simantov resigned as Director at Tempest Therapeutics, Inc..","evidence_excerpt":"On May 23, 2026, Ms. Simantov notified Tempest Therapeutics, Inc. (the \"Company\") of her resignation from the Board of Directors of the Company (the \"Board\"), effective as of such date.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-26-248648","anchor_url":"https://secwatch.observer/filing/0001193125-26-248648#claim-561bc49325","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1544227/000119312526248648/0001193125-26-248648-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"9b80a33cda5d7954fa530eff935c3a1e456bec4a","cik":1544227,"ticker":"TPST","company_name":"Tempest Therapeutics, Inc.","filed_at":"2026-05-22T21:28:16+00:00","payload":{"company_response":null,"compliance_status":"deficient","cure_deadline":null,"deficiency_type":"board_independence","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2026-05-22","notice_type":"noncompliance_notice","plan_due_date":null,"raw_rule_text":null,"reported_value":null,"rule_numbers":[],"rules_cited_in_text":false},"claim":"Tempest Therapeutics, Inc. received a nasdaq noncompliance notice notice regarding board independence.","evidence_excerpt":"May 22, 2026, Tempest Therapeutics, Inc. (the “Company”) notified the Nasdaq Stock Market LLC (“Nasdaq”) that the Company will not be in compliance with the majority independent director requirement under Nasdaq Listing","confidence":0.8,"filing_url":"https://secwatch.observer/filing/0001193125-26-237207","anchor_url":"https://secwatch.observer/filing/0001193125-26-237207#claim-9b80a33cda5d7954fa530eff935c3a1e456bec4a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1544227/000119312526237207/0001193125-26-237207-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"f73f9a17ab8a4f3f20cdd08462e9c61b5b43e174","cik":1544227,"ticker":"TPST","company_name":"Tempest Therapeutics, Inc.","filed_at":"2026-05-22T21:28:16+00:00","payload":{"company_response":"Company intends to submit a compliance plan on or before July 6, 2026.","compliance_status":"plan_due","cure_deadline":null,"deficiency_type":"stockholders_equity","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":"2500000","notice_date":"2026-05-19","notice_type":"deficiency_notice","plan_due_date":"2026-07-06","raw_rule_text":null,"reported_value":"822000","rule_numbers":["5550(b)(1)"],"rules_cited_in_text":true},"claim":"Tempest Therapeutics, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).","evidence_excerpt":"May 19, 2026, Tempest Therapeutics, Inc. (the “Company”) received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that it is not in","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-26-237207","anchor_url":"https://secwatch.observer/filing/0001193125-26-237207#claim-f73f9a17ab8a4f3f20cdd08462e9c61b5b43e174","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1544227/000119312526237207/0001193125-26-237207-index.htm"},{"fact_type":"executive_change","fact_key":"564bab896c","cik":1544227,"ticker":"TPST","company_name":"Tempest Therapeutics, Inc.","filed_at":"2026-05-22T21:28:16+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"not_disclosed","effective_date":null,"interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Christine Pellizzari resigned as Director at Tempest Therapeutics, Inc..","evidence_excerpt":"resignations of Mr. Michael Raab and Ms. Christine Pellizzari from the Board","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-26-237207","anchor_url":"https://secwatch.observer/filing/0001193125-26-237207#claim-564bab896c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1544227/000119312526237207/0001193125-26-237207-index.htm"},{"fact_type":"executive_change","fact_key":"c42bb19772","cik":1544227,"ticker":"TPST","company_name":"Tempest Therapeutics, Inc.","filed_at":"2026-05-22T21:28:16+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"not_disclosed","effective_date":null,"interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Michael Raab resigned as Director at Tempest Therapeutics, Inc..","evidence_excerpt":"resignations of Mr. Michael Raab and Ms. Christine Pellizzari from the Board","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-26-237207","anchor_url":"https://secwatch.observer/filing/0001193125-26-237207#claim-c42bb19772","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1544227/000119312526237207/0001193125-26-237207-index.htm"},{"fact_type":"executive_change","fact_key":"5310339e24","cik":1544227,"ticker":"TPST","company_name":"Tempest Therapeutics, Inc.","filed_at":"2026-05-22T21:05:53+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2026-05-22","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Christine Pellizzari resigned as Director at Tempest Therapeutics, Inc..","evidence_excerpt":"On May 22, 2026, each of Mr. Stephen Brady, Mr. Michael Raab and Ms. Christine Pellizzari notified Tempest Therapeutics, Inc. (the “Company”) of his or her resignation from the Board of Directors of the Company (the “Board”), effective as of such date.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-26-237150","anchor_url":"https://secwatch.observer/filing/0001193125-26-237150#claim-5310339e24","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1544227/000119312526237150/0001193125-26-237150-index.htm"},{"fact_type":"executive_change","fact_key":"6b76a16d94","cik":1544227,"ticker":"TPST","company_name":"Tempest Therapeutics, Inc.","filed_at":"2026-05-22T21:05:53+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2026-05-22","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Michael Raab resigned as Director at Tempest Therapeutics, Inc..","evidence_excerpt":"On May 22, 2026, each of Mr. Stephen Brady, Mr. Michael Raab and Ms. Christine Pellizzari notified Tempest Therapeutics, Inc. (the “Company”) of his or her resignation from the Board of Directors of the Company (the “Board”), effective as of such date.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-26-237150","anchor_url":"https://secwatch.observer/filing/0001193125-26-237150#claim-6b76a16d94","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1544227/000119312526237150/0001193125-26-237150-index.htm"},{"fact_type":"executive_change","fact_key":"7d5fc56857","cik":1544227,"ticker":"TPST","company_name":"Tempest Therapeutics, Inc.","filed_at":"2026-05-22T21:05:53+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2026-05-22","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Stephen Brady resigned as Director at Tempest Therapeutics, Inc..","evidence_excerpt":"On May 22, 2026, each of Mr. Stephen Brady, Mr. Michael Raab and Ms. Christine Pellizzari notified Tempest Therapeutics, Inc. (the “Company”) of his or her resignation from the Board of Directors of the Company (the “Board”), effective as of such date.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-26-237150","anchor_url":"https://secwatch.observer/filing/0001193125-26-237150#claim-7d5fc56857","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1544227/000119312526237150/0001193125-26-237150-index.htm"},{"fact_type":"earnings_release","fact_key":"b9cfb3fe0e1d2eec50533a5404695cd4c67df8c7","cik":1544227,"ticker":"TPST","company_name":"Tempest Therapeutics, Inc.","filed_at":"2026-05-14T20:28:56+00:00","payload":{"eps_text":"$2.53","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$27.7 million","period_text":"the quarter ended March 31, 2026","report_date":"2026-05-14","result_type":"reported_results","revenue_text":null},"claim":"Tempest Therapeutics, Inc. reported the quarter ended March 31, 2026 results: net income $27.7 million, EPS $2.53.","evidence_excerpt":"Net loss and net loss per share for the quarter were $27.7 million and $2.53, respectively, compared to $10.9 million and $3.16, respectively, for the three months ended March 31, 2025.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-224156","anchor_url":"https://secwatch.observer/filing/0001193125-26-224156#claim-b9cfb3fe0e1d2eec50533a5404695cd4c67df8c7","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1544227/000119312526224156/0001193125-26-224156-index.htm"},{"fact_type":"earnings_release","fact_key":"15dff7b84fb61a1d98c85edddc9a655b8bd59a6f","cik":1544227,"ticker":"TPST","company_name":"Tempest Therapeutics, Inc.","filed_at":"2026-03-30T23:59:59+00:00","payload":{"eps_text":"$6.33","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"Net loss and net loss per share for the year were $26.3 million and $6.33, respectively","period_text":"year ended December 31, 2025","report_date":"2026-03-30","result_type":"reported_results","revenue_text":null},"claim":"Tempest Therapeutics, Inc. reported year ended December 31, 2025 results: net income Net loss and net loss per share for the year were $26.3 million and $6.33, respectively, EPS $6.33.","evidence_excerpt":"from the RDO in June, $3.8 million from the November Offering and $2.8 million from Tempest’s at-the-market offering program. • Net loss and net loss per share for the year were $26.3 million and $6.33, respectively, compared to $41.8 million and $19.50, respectively, for the same period in 2024. • Research and development expenses for the year were $12.6 million","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-26-130480","anchor_url":"https://secwatch.observer/filing/0001193125-26-130480#claim-15dff7b84fb61a1d98c85edddc9a655b8bd59a6f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1544227/000119312526130480/0001193125-26-130480-index.htm"},{"fact_type":"equity_issuance","fact_key":"2a317290a5c2405126b0a851439533847e8f6d67","cik":1544227,"ticker":"TPST","company_name":"Tempest Therapeutics, Inc.","filed_at":"2026-03-23T23:59:59+00:00","payload":{"action":"warrant_issuance","consideration_text":"Included in the combined purchase price of $2.16 per share or $2.159 per pre-funded warrant","effective_date":"2026-03-23","item_codes_triggered":["3.02"],"purchaser":"two institutional investors and Factor Bioscience Inc.","security_type":"warrant","shares_text":"Series A warrants to purchase up to 925,927 shares of common stock and Series B warrants to purchase up to 925,927 shares of common stock"},"claim":"Tempest Therapeutics, Inc. issued Series A warrants to purchase up to 925,927 shares of common stock and Series B warrants to purchase up to 925,927 shares of common stock of warrant to two institutional investors and Factor Bioscience Inc. for Included in the combined purchase price of $2.16 per share or $2.159 per pre-funded warrant.","evidence_excerpt":"”). The Shares and the Common Warrants are immediately separable and will be issued separately. The combined purchase price per Share and accompanying Common Warrants is $2.16 and the combined purchase price per Pre-Funded Warrant and accompanying Common Warrants is $2.159. The gross proceeds to the Company from the Private Placement are expected to be","confidence":0.98,"filing_url":"https://secwatch.observer/filing/0001193125-26-118618","anchor_url":"https://secwatch.observer/filing/0001193125-26-118618#claim-2a317290a5c2405126b0a851439533847e8f6d67","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1544227/000119312526118618/0001193125-26-118618-index.htm"},{"fact_type":"equity_issuance","fact_key":"4870ab6f7e05b71d6441434706f3e46245050c18","cik":1544227,"ticker":"TPST","company_name":"Tempest Therapeutics, Inc.","filed_at":"2026-03-23T23:59:59+00:00","payload":{"action":"private_placement","consideration_text":"$2.159 per pre-funded warrant and accompanying common warrants","effective_date":"2026-03-23","item_codes_triggered":["3.02"],"purchaser":"two institutional investors and Factor Bioscience Inc.","security_type":"warrant","shares_text":"Pre-funded warrants to purchase 462,963 shares of common stock"},"claim":"Tempest Therapeutics, Inc. issued Pre-funded warrants to purchase 462,963 shares of common stock of warrant to two institutional investors and Factor Bioscience Inc. for $2.159 per pre-funded warrant and accompanying common warrants.","evidence_excerpt":"”). The Shares and the Common Warrants are immediately separable and will be issued separately. The combined purchase price per Share and accompanying Common Warrants is $2.16 and the combined purchase price per Pre-Funded Warrant and accompanying Common Warrants is $2.159. The gross proceeds to the Company from the Private Placement are expected to be","confidence":0.98,"filing_url":"https://secwatch.observer/filing/0001193125-26-118618","anchor_url":"https://secwatch.observer/filing/0001193125-26-118618#claim-4870ab6f7e05b71d6441434706f3e46245050c18","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1544227/000119312526118618/0001193125-26-118618-index.htm"},{"fact_type":"equity_issuance","fact_key":"2c3eddc7af27ee3aa35c5a440dcff20a5d6e1aae","cik":1544227,"ticker":"TPST","company_name":"Tempest Therapeutics, Inc.","filed_at":"2026-03-23T23:59:59+00:00","payload":{"action":"private_placement","consideration_text":"$2.16 per share and accompanying common warrants, aggregate gross proceeds approximately $2.0 million","effective_date":"2026-03-23","item_codes_triggered":["3.02"],"purchaser":"two institutional investors and Factor Bioscience Inc.","security_type":"common_stock","shares_text":"462,964 shares of common stock"},"claim":"Tempest Therapeutics, Inc. issued 462,964 shares of common stock of common stock to two institutional investors and Factor Bioscience Inc. for $2.16 per share and accompanying common warrants, aggregate gross proceeds approximately $2.0 million.","evidence_excerpt":"”). The Shares and the Common Warrants are immediately separable and will be issued separately. The combined purchase price per Share and accompanying Common Warrants is $2.16 and the combined purchase price per Pre-Funded Warrant and accompanying Common Warrants is $2.159. The gross proceeds to the Company from the Private Placement are expected to be","confidence":0.98,"filing_url":"https://secwatch.observer/filing/0001193125-26-118618","anchor_url":"https://secwatch.observer/filing/0001193125-26-118618#claim-2c3eddc7af27ee3aa35c5a440dcff20a5d6e1aae","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1544227/000119312526118618/0001193125-26-118618-index.htm"},{"fact_type":"material_agreement","fact_key":"a7d3de3810b7488533012061206b1ba1d77b0365","cik":1544227,"ticker":"TPST","company_name":"Tempest Therapeutics, Inc.","filed_at":"2026-03-23T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Registration Rights Agreement","agreement_type":"equity_purchase","counterparty":"Institutional Investors and Factor Bioscience Inc.","effective_date":"2026-03-20","item_codes_triggered":["1.01"],"value_text":"Obligation to file resale registration statement within 15 calendar days and use best efforts to hav"},"claim":"Tempest Therapeutics, Inc. entered into Registration Rights Agreement with Institutional Investors and Factor Bioscience Inc. valued at Obligation to file resale registration statement within 15 calendar days and use best efforts to hav (effective 2026-03-20).","evidence_excerpt":"On March 20, 2026, the Company also entered into a registration rights agreement with the Investors (the “ Registration Rights Agreement ”), pursuant to which the Company agreed to file registration statements under the Securities Act, with the Securities and Exchange Commission (the “ SEC ”), covering the resale of the Shares to be issued in the Private Placement and the shares of Common Stock underlying the Common Warrants and Pre-Funded Warrants no later than 15 calendar days following the date of the Purchase Agreement, and to use reasonable best efforts to have the registration statement declared effective by 45 calendar days following the date of the Purchase Agreement, and in any event no later than 75 calendar days following the date of the Purchase Agreement in the event of a “full review” by the SEC (the “ Effectiveness Date ”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-118618","anchor_url":"https://secwatch.observer/filing/0001193125-26-118618#claim-a7d3de3810b7488533012061206b1ba1d77b0365","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1544227/000119312526118618/0001193125-26-118618-index.htm"},{"fact_type":"material_agreement","fact_key":"28f8b2413d0771d8afbee5d9cb2f794c6722eeda","cik":1544227,"ticker":"TPST","company_name":"Tempest Therapeutics, Inc.","filed_at":"2026-03-23T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Securities Purchase Agreement","agreement_type":"equity_purchase","counterparty":"Institutional Investors and Factor Bioscience Inc.","effective_date":"2026-03-20","item_codes_triggered":["1.01"],"value_text":"Aggregate gross proceeds of approximately $2.0 million from the sale of 462,964 shares and pre-funde"},"claim":"Tempest Therapeutics, Inc. entered into Securities Purchase Agreement with Institutional Investors and Factor Bioscience Inc. valued at Aggregate gross proceeds of approximately $2.0 million from the sale of 462,964 shares and pre-funde (effective 2026-03-20).","evidence_excerpt":"On March 20, 2026, Tempest Therapeutics, Inc. (the “ Company ”) entered into a securities purchase agreement (the “ Purchase Agreement ”) with (a) two institutional investors (the “ Institutional Investors ”) and (b) Factor Bioscience Inc. (the “ Strategic Investor ” and, together with the Institutional Investors, each, an “ Investor ” and, together, the “ Investors ”), pursuant to which the Company agreed to issue and sell in a private placement (the “ Private Placement ”) an aggregate of 462,964 shares (the “ Shares ”) of the Company’s common stock, $0.001 par value per share (the “ Common Stock ”), and, in lieu of Common Stock, pre-funded warrants to purchase up to 462,963 shares of Common Stock (the “ Pre-Funded Warrants ”), in each case accompanied by (i) Series A warrants to purchase up to 925,927 shares of Common Stock (the “ Series A Warrants ”) and (ii) Series B warrants to purchase up to 925,927 shares of Common Stock (the “ Series B Warrants ” and, together with the Series A","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-118618","anchor_url":"https://secwatch.observer/filing/0001193125-26-118618#claim-28f8b2413d0771d8afbee5d9cb2f794c6722eeda","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1544227/000119312526118618/0001193125-26-118618-index.htm"},{"fact_type":"equity_issuance","fact_key":"f1143d3e933ad1a3af45539b70c967b371ba2992","cik":1544227,"ticker":"TPST","company_name":"Tempest Therapeutics, Inc.","filed_at":"2026-02-06T23:59:59+00:00","payload":{"action":"private_placement","consideration_text":"aggregate purchase price included in the Asset Purchase Agreement","effective_date":"2026-02-06","item_codes_triggered":["3.02"],"purchaser":"Erigen (on behalf of Sellers under the Asset Purchase Agreement)","security_type":"common_stock","shares_text":"8,268,495 shares of Common Stock"},"claim":"Tempest Therapeutics, Inc. issued 8,268,495 shares of Common Stock of common stock to Erigen (on behalf of Sellers under the Asset Purchase Agreement) for aggregate purchase price included in the Asset Purchase Agreement.","evidence_excerpt":"in exchange for an aggregate purchase price of 8,268,495 shares of common stock, par value $0.001 per share, of the Company (“ Common Stock ”), to be issued to Erigen on behalf of both Sellers.","confidence":0.8,"filing_url":"https://secwatch.observer/filing/0001193125-26-041190","anchor_url":"https://secwatch.observer/filing/0001193125-26-041190#claim-f1143d3e933ad1a3af45539b70c967b371ba2992","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1544227/000119312526041190/0001193125-26-041190-index.htm"},{"fact_type":"equity_issuance","fact_key":"aa48dd7782b523bff0480b5122c683324ef49be2","cik":1544227,"ticker":"TPST","company_name":"Tempest Therapeutics, Inc.","filed_at":"2026-02-06T23:59:59+00:00","payload":{"action":"warrant_issuance","consideration_text":"issued as a dividend on each share of Common Stock outstanding on the Record Date","effective_date":"2026-02-03","item_codes_triggered":["3.02"],"purchaser":"shareholders of record","security_type":"warrant","shares_text":"6,784,989 Warrants"},"claim":"Tempest Therapeutics, Inc. issued 6,784,989 Warrants of warrant to shareholders of record for issued as a dividend on each share of Common Stock outstanding on the Record Date.","evidence_excerpt":"On January 20, 2026, the Company issued a press release announcing that its Board of Directors (the “ Board ”) declared a record date of January 30, 2026 (the “ Record Date ”) for the distribution of a dividend (the “ Warrant Dividend ”) in the form of a warrant to purchase a share of Common Stock (collectively, the “ Warrants ”) for each share of Common Stock outstanding on the Record Date.","confidence":0.85,"filing_url":"https://secwatch.observer/filing/0001193125-26-041190","anchor_url":"https://secwatch.observer/filing/0001193125-26-041190#claim-aa48dd7782b523bff0480b5122c683324ef49be2","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1544227/000119312526041190/0001193125-26-041190-index.htm"},{"fact_type":"ma_transaction","fact_key":"9a36e2083ee215219bbcd0b71a931088dd23c130","cik":1544227,"ticker":"TPST","company_name":"Tempest Therapeutics, Inc.","filed_at":"2026-02-06T23:59:59+00:00","payload":{"action":"acquisition","closing_date":"2026-02-03","consideration_text":"8,268,495 shares of common stock","counterparty":"Erigen LLC (on behalf of itself and Factor Bioscience Inc.)","effective_date":"2026-02-03","item_codes_triggered":["2.01"]},"claim":"Tempest Therapeutics, Inc. completed an acquisition involving Erigen LLC (on behalf of itself and Factor Bioscience Inc.) for 8,268,495 shares of common stock (closed 2026-02-03).","evidence_excerpt":"On February 3, 2026, the Company completed the acquisition of the Assets under the Asset Purchase Agreement (the “ Asset Acquisition ”) and issued to Erigen 8,268,495 shares of Common Stock","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-041190","anchor_url":"https://secwatch.observer/filing/0001193125-26-041190#claim-9a36e2083ee215219bbcd0b71a931088dd23c130","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1544227/000119312526041190/0001193125-26-041190-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"af22f484dffeb8465b6c9f0cdb62bf2f918b341d","cik":1544227,"ticker":"TPST","company_name":"Tempest Therapeutics, Inc.","filed_at":"2026-01-09T23:59:59+00:00","payload":{"company_response":"plan to hold annual meeting on January 27, 2026","compliance_status":"deficient","cure_deadline":"2026-02-23","deficiency_type":"other","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":"annual meeting within 12 months of fiscal year end","notice_date":"2026-01-08","notice_type":"deficiency_notice","plan_due_date":"2026-02-23","raw_rule_text":null,"reported_value":null,"rule_numbers":["5620(a)","5810(c)(2)(G)"],"rules_cited_in_text":true},"claim":"Tempest Therapeutics, Inc. received a nasdaq deficiency notice notice regarding other (rules 5620(a), 5810(c)(2)(G)).","evidence_excerpt":"January 8, 2026, the Company received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, due to the Company’s failure to hold an annual meeting of stockholders within twelve months of the end of the Company’s fiscal year end of December 31, 2024, it is not in compliance with the continued listing requirements of Nasdaq Listing Rules 5620(a) and 5810(c)(2)(G) (the “Nasdaq Annual Meeting Requirement”). Under Nasdaq Listing Rules, the Company has 45 calendar days from January 8, 2026, or until February 23, 2026, to regain compliance or s","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-008938","anchor_url":"https://secwatch.observer/filing/0001193125-26-008938#claim-af22f484dffeb8465b6c9f0cdb62bf2f918b341d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1544227/000119312526008938/0001193125-26-008938-index.htm"},{"fact_type":"equity_issuance","fact_key":"0dd8c075d77aa24f91ea60e11dbc0eb268ff5f54","cik":1544227,"ticker":"TPST","company_name":"Tempest Therapeutics, Inc.","filed_at":"2025-11-26T23:59:59+00:00","payload":{"action":"private_placement","consideration_text":"exercise price of $3.50 per share","effective_date":"2025-11-25","item_codes_triggered":["3.02"],"purchaser":"a single healthcare-focused institutional investor","security_type":"warrant","shares_text":"warrants to purchase up to an aggregate of 1,172,414 shares of common stock"},"claim":"Tempest Therapeutics, Inc. issued warrants to purchase up to an aggregate of 1,172,414 shares of common stock of warrant to a single healthcare-focused institutional investor for exercise price of $3.50 per share.","evidence_excerpt":"in a concurrent private placement, the Company will issue and sell short-term unregistered warrants to purchase up to an aggregate of 1,172,414 shares of common stock at an exercise price of $3.50 per share","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-25-298604","anchor_url":"https://secwatch.observer/filing/0001193125-25-298604#claim-0dd8c075d77aa24f91ea60e11dbc0eb268ff5f54","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1544227/000119312525298604/0001193125-25-298604-index.htm"},{"fact_type":"equity_issuance","fact_key":"a26da2dfc5b2c52da5f3420cc4221dd905870031","cik":1544227,"ticker":"TPST","company_name":"Tempest Therapeutics, Inc.","filed_at":"2025-11-26T23:59:59+00:00","payload":{"action":"registered_direct","consideration_text":"$3.625 per share","effective_date":"2025-11-25","item_codes_triggered":["3.02"],"purchaser":"a single healthcare-focused institutional investor","security_type":"common_stock","shares_text":"1,172,414 shares of its common stock (or common stock equivalents)"},"claim":"Tempest Therapeutics, Inc. issued 1,172,414 shares of its common stock (or common stock equivalents) of common stock to a single healthcare-focused institutional investor for $3.625 per share.","evidence_excerpt":"the purchase and sale of 1,172,414 shares of its common stock (or common stock equivalents), at an offering price of $3.625 per share of common stock (or common stock equivalent) in a registered direct offering priced at-the-market under Nasdaq rules","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-25-298604","anchor_url":"https://secwatch.observer/filing/0001193125-25-298604#claim-a26da2dfc5b2c52da5f3420cc4221dd905870031","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1544227/000119312525298604/0001193125-25-298604-index.htm"},{"fact_type":"restructuring_charge","fact_key":"1093a1d6beced77125208d1a6f97f2bde9ccda49","cik":1544227,"ticker":"TPST","company_name":"Tempest Therapeutics, Inc.","filed_at":"2025-04-18T23:59:59+00:00","payload":{"affected_area":null,"charge_text":"approximately $1.5 million","effective_date":"2025-04-17","event_type":"restructuring","headcount_text":"21 of 26 full-time employees","item_codes_triggered":["2.05"]},"claim":"Tempest Therapeutics, Inc. announced a restructuring with charges of approximately $1.5 million (21 of 26 full-time employees).","evidence_excerpt":"that key employees within this group will transition to consulting agreements and continue to be available to the Company. The Company estimates that it will incur approximately $1.5 million of cash expenditures, consisting primarily of one-time severance payments, benefits and other related costs (excluding non-cash charges associated with equity-based","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-25-085773","anchor_url":"https://secwatch.observer/filing/0001193125-25-085773#claim-1093a1d6beced77125208d1a6f97f2bde9ccda49","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1544227/000119312525085773/0001193125-25-085773-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"aebf6653ff7e8784a887f7cb8c5a5d1e2a9c9784","cik":1544227,"ticker":"TPST","company_name":"Tempest Therapeutics, Inc.","filed_at":"2024-12-31T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"deficient","cure_deadline":null,"deficiency_type":"minimum_bid_price","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2024-12-27","notice_type":"deficiency_notice","plan_due_date":null,"raw_rule_text":null,"reported_value":null,"rule_numbers":["5550(a)(2)","5810(c)(3)(A)"],"rules_cited_in_text":true},"claim":"Tempest Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).","evidence_excerpt":"December 27, 2024, Tempest Therapeutics, Inc., a Delaware corporation (the “Company”), received a letter from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the last 30 consecutive business days, the bid price of the Company’s common stock had closed below $1.00 per share, the minimum closing bid price required by the continued listing requirements of Nasdaq Listing Rule 5550(a)(2). The notification received has no immediate effect on the listing of the Company’s common stock on the Nasdaq Stock Market. In accordance with","confidence":0.97,"filing_url":"https://secwatch.observer/filing/0001193125-24-287170","anchor_url":"https://secwatch.observer/filing/0001193125-24-287170#claim-aebf6653ff7e8784a887f7cb8c5a5d1e2a9c9784","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1544227/000119312524287170/0001193125-24-287170-index.htm"},{"fact_type":"earnings_release","fact_key":"738f66e41854ad6d573c970a6da4cd95b87212a4","cik":1544227,"ticker":"TPST","company_name":"Tempest Therapeutics, Inc.","filed_at":"2024-05-09T23:59:59+00:00","payload":{"eps_text":"$0.36","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$7.9 million","period_text":"the quarter ended March 31, 2024","report_date":"2024-05-09","result_type":"reported_results","revenue_text":null},"claim":"Tempest Therapeutics, Inc. reported the quarter ended March 31, 2024 results: net income $7.9 million, EPS $0.36.","evidence_excerpt":"Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class i targeted and immune-mediated therapeutics to fight cancer, today reported financial results for the quarter ended March 31, 2024, and provided a corporate update.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-24-057047","anchor_url":"https://secwatch.observer/filing/0000950170-24-057047#claim-738f66e41854ad6d573c970a6da4cd95b87212a4","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1544227/000095017024057047/0000950170-24-057047-index.htm"},{"fact_type":"earnings_release","fact_key":"c279f8dd2fe28fbf208c0338e8210b42d268d70f","cik":1544227,"ticker":"TPST","company_name":"Tempest Therapeutics, Inc.","filed_at":"2024-03-19T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"year ended December 31, 2023","report_date":"2024-03-19","result_type":"reported_results","revenue_text":null},"claim":"Tempest Therapeutics, Inc. reported financial results for year ended December 31, 2023.","evidence_excerpt":"On March 19, 2024, Tempest Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the year ended December 31, 2023 and other business highlights.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-24-033464","anchor_url":"https://secwatch.observer/filing/0000950170-24-033464#claim-c279f8dd2fe28fbf208c0338e8210b42d268d70f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1544227/000095017024033464/0000950170-24-033464-index.htm"},{"fact_type":"earnings_release","fact_key":"730de07783a16c43e9decf428516b51a556ca1e1","cik":1544227,"ticker":"TPST","company_name":"Tempest Therapeutics, Inc.","filed_at":"2023-11-08T23:59:59+00:00","payload":{"eps_text":"$1.57 per share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$22.0 million","period_text":"the nine months ended September 30, 2023","report_date":"2023-11-08","result_type":"reported_results","revenue_text":null},"claim":"Tempest Therapeutics, Inc. reported the nine months ended September 30, 2023 results: net income $22.0 million, EPS $1.57 per share.","evidence_excerpt":"Net loss and net loss per share for the nine months ended September 30, 2023 were $22.0 million and $1.57, respectively, compared to $26.6 million and $2.46, respectively, for the same period in 2022.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-23-061271","anchor_url":"https://secwatch.observer/filing/0000950170-23-061271#claim-730de07783a16c43e9decf428516b51a556ca1e1","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1544227/000095017023061271/0000950170-23-061271-index.htm"},{"fact_type":"earnings_release","fact_key":"dde26323283fb29c10e93a09021e22cde4239f00","cik":1544227,"ticker":"TPST","company_name":"Tempest Therapeutics, Inc.","filed_at":"2023-11-08T23:59:59+00:00","payload":{"eps_text":"$0.48 per share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$6.8 million","period_text":"the quarter ended September 30, 2023","report_date":"2023-11-08","result_type":"reported_results","revenue_text":null},"claim":"Tempest Therapeutics, Inc. reported the quarter ended September 30, 2023 results: net income $6.8 million, EPS $0.48 per share.","evidence_excerpt":"Net loss and net loss per share for the quarter ended September 30, 2023 were $6.8 million and $0.48, respectively, compared to $8.9 million and $0.66, respectively, for the same period in 2022.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-23-061271","anchor_url":"https://secwatch.observer/filing/0000950170-23-061271#claim-dde26323283fb29c10e93a09021e22cde4239f00","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1544227/000095017023061271/0000950170-23-061271-index.htm"},{"fact_type":"material_agreement","fact_key":"a4e93ca0a2277129f2e82e106abcc952f71fe079","cik":1544227,"ticker":"TPST","company_name":"Tempest Therapeutics, Inc.","filed_at":"2023-10-11T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Rights Agreement","agreement_type":"other","counterparty":"Computershare Trust Company, N.A.","effective_date":"2023-10-10","item_codes_triggered":["1.01"],"value_text":null},"claim":"Tempest Therapeutics, Inc. entered into Rights Agreement with Computershare Trust Company, N.A. (effective 2023-10-10).","evidence_excerpt":"the Rights Agreement, dated as of October 10, 2023 (the “Rights Agreement”), by and between the Company and Computershare Trust Company, N.A., as Rights Agent","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-23-253882","anchor_url":"https://secwatch.observer/filing/0001193125-23-253882#claim-a4e93ca0a2277129f2e82e106abcc952f71fe079","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1544227/000119312523253882/0001193125-23-253882-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"01ad97c8953fa82b4f374ddf2bb3b4187f093cc7","cik":1544227,"ticker":"TPST","company_name":"Tempest Therapeutics, Inc.","filed_at":"2023-09-08T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"deficient","cure_deadline":"2024-03-04","deficiency_type":"minimum_bid_price","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":false,"minimum_requirement":"$1.00 per share","notice_date":"2023-09-06","notice_type":"deficiency_notice","plan_due_date":null,"raw_rule_text":"Nasdaq Listing Rule 5550(a)(2)","reported_value":"below $1.00 per share for 30 consecutive business days","rule_numbers":["5550(a)(2)"],"rules_cited_in_text":true},"claim":"Tempest Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).","evidence_excerpt":"September 6, 2023, Tempest Therapeutics, Inc., a Delaware corporation (the “Company”), received a letter from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the last 30 consecutive business days, the bid price of the Company’s common stock had closed below $1.00 per share, the minimum closing bid price required by the continued listing requirements of Nasdaq Listing Rule 5550(a)(2). The notification received has no immediate effect on the listing of the Company’s common stock on the Nasdaq Stock Market. In accordance with","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-23-231557","anchor_url":"https://secwatch.observer/filing/0001193125-23-231557#claim-01ad97c8953fa82b4f374ddf2bb3b4187f093cc7","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1544227/000119312523231557/0001193125-23-231557-index.htm"},{"fact_type":"executive_change","fact_key":"b4cb24c028","cik":1544227,"ticker":"TPST","company_name":"Tempest Therapeutics, Inc.","filed_at":"2023-09-07T23:59:59+00:00","payload":{"action":"appointed","action_category":"role_change","departure_tone":"not_applicable","effective_date":"2023-09-15","interim":false,"role":"President and Chief Executive Officer","role_category":"ceo","successor_name":null,"successor_named":false},"claim":"Stephen Brady was appointed as President and Chief Executive Officer at Tempest Therapeutics, Inc..","evidence_excerpt":"the Board will appoint Stephen Brady, the Company’s chief executive officer, as president and chief executive officer effective as of the Separation Date","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001193125-23-230659","anchor_url":"https://secwatch.observer/filing/0001193125-23-230659#claim-b4cb24c028","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1544227/000119312523230659/0001193125-23-230659-index.htm"},{"fact_type":"executive_change","fact_key":"f9d031ff99","cik":1544227,"ticker":"TPST","company_name":"Tempest Therapeutics, Inc.","filed_at":"2023-09-07T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2023-09-02","interim":false,"role":"President and member of the Board of Directors","role_category":"president","successor_name":"Stephen Brady","successor_named":true},"claim":"Tom Dubensky resigned as President and member of the Board of Directors at Tempest Therapeutics, Inc..","evidence_excerpt":"On September 2, 2023, Tom Dubensky, Ph.D. resigned from his role as president and member of the Board of Directors","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001193125-23-230659","anchor_url":"https://secwatch.observer/filing/0001193125-23-230659#claim-f9d031ff99","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1544227/000119312523230659/0001193125-23-230659-index.htm"},{"fact_type":"earnings_release","fact_key":"eca4061ffe3309f69f0b1650a6d334cf2a6b0927","cik":1544227,"ticker":"TPST","company_name":"Tempest Therapeutics, Inc.","filed_at":"2023-08-10T23:59:59+00:00","payload":{"eps_text":"$1.09","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"Net loss and net loss per share for the six months ended June 30, 2023 were $15.2 million and $1.09, respectively","period_text":"the six months ended June 30, 2023","report_date":"2023-08-10","result_type":"reported_results","revenue_text":null},"claim":"Tempest Therapeutics, Inc. reported the six months ended June 30, 2023 results: net income Net loss and net loss per share for the six months ended June 30, 2023 were $15.2 million and $1.09, respectively, EPS $1.09.","evidence_excerpt":"Net loss and net loss per share for the six months ended June 30, 2023 were $15.2 million and $1.09, respectively, compared to $17.7 million and $1.88, respectively, for the same period in 2022.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-23-041385","anchor_url":"https://secwatch.observer/filing/0000950170-23-041385#claim-eca4061ffe3309f69f0b1650a6d334cf2a6b0927","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1544227/000095017023041385/0000950170-23-041385-index.htm"},{"fact_type":"earnings_release","fact_key":"0781e05bb0cb8cbe9bff39a4e5f74383168c8a2e","cik":1544227,"ticker":"TPST","company_name":"Tempest Therapeutics, Inc.","filed_at":"2023-08-10T23:59:59+00:00","payload":{"eps_text":"$0.54","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"Net loss and net loss per share for the quarter ended June 30, 2023 were $7.6 million and $0.54, respectively","period_text":"the quarter ended June 30, 2023","report_date":"2023-08-10","result_type":"reported_results","revenue_text":null},"claim":"Tempest Therapeutics, Inc. reported the quarter ended June 30, 2023 results: net income Net loss and net loss per share for the quarter ended June 30, 2023 were $7.6 million and $0.54, respectively, EPS $0.54.","evidence_excerpt":"Net loss and net loss per share for the quarter ended June 30, 2023 were $7.6 million and $0.54, respectively, compared to $9.2 million and $0.79, respectively, for the same period in 2022.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-23-041385","anchor_url":"https://secwatch.observer/filing/0000950170-23-041385#claim-0781e05bb0cb8cbe9bff39a4e5f74383168c8a2e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1544227/000095017023041385/0000950170-23-041385-index.htm"},{"fact_type":"shareholder_vote","fact_key":"30d2de9fe014e48a35cf9d58c540a7871d66c144","cik":1544227,"ticker":"TPST","company_name":"Tempest Therapeutics, Inc.","filed_at":"2023-06-16T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-06-15","outcome":"passed","proposal_text":"Ratification of the Selection of Independent Registered Public Accounting Firm","proposal_type":"auditor_ratification","results":[{"broker_non_votes":"—","subject":null,"votes_abstain":"3,870","votes_against":null,"votes_for":"8,852,927","votes_withheld":"45,456"}]},"claim":"Tempest Therapeutics, Inc. shareholders approved Ratification of the Selection of Independent Registered Public Accounting Firm at the 2023-06-15 meeting.","evidence_excerpt":"The Company’s stockholders ratified the selection of Ernst & Young LLP by the Audit Committee of the Board as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-23-169021","anchor_url":"https://secwatch.observer/filing/0001193125-23-169021#claim-30d2de9fe014e48a35cf9d58c540a7871d66c144","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1544227/000119312523169021/0001193125-23-169021-index.htm"},{"fact_type":"shareholder_vote","fact_key":"36f559f8e4310c125f26c68c60ba757b95bc0d49","cik":1544227,"ticker":"TPST","company_name":"Tempest Therapeutics, Inc.","filed_at":"2023-06-16T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-06-15","outcome":"passed","proposal_text":"Approval, on an advisory basis, of the compensation of the Company’s named executive officers","proposal_type":"say_on_pay","results":[{"broker_non_votes":"1,352,424","subject":null,"votes_abstain":"138,547","votes_against":null,"votes_for":"7,355,907","votes_withheld":"55,375"}]},"claim":"Tempest Therapeutics, Inc. shareholders approved Approval, on an advisory basis, of the compensation of the Company’s named executive officers at the 2023-06-15 meeting.","evidence_excerpt":"The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-23-169021","anchor_url":"https://secwatch.observer/filing/0001193125-23-169021#claim-36f559f8e4310c125f26c68c60ba757b95bc0d49","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1544227/000119312523169021/0001193125-23-169021-index.htm"},{"fact_type":"shareholder_vote","fact_key":"4fa412369c7b2ba03701d3b5dd81615396cb0a2e","cik":1544227,"ticker":"TPST","company_name":"Tempest Therapeutics, Inc.","filed_at":"2023-06-16T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-06-15","outcome":"passed","proposal_text":"Approval of the Amended and Restated 2023 Equity Incentive Plan","proposal_type":"equity_plan","results":[{"broker_non_votes":"1,352,424","subject":null,"votes_abstain":"147,473","votes_against":null,"votes_for":"6,978,751","votes_withheld":"423,605"}]},"claim":"Tempest Therapeutics, Inc. shareholders approved Approval of the Amended and Restated 2023 Equity Incentive Plan at the 2023-06-15 meeting.","evidence_excerpt":"The Company’s stockholders ratified the 2023 EIP, which amends, restates and will be a successor to, and replacement of, the 2019 EIP.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-23-169021","anchor_url":"https://secwatch.observer/filing/0001193125-23-169021#claim-4fa412369c7b2ba03701d3b5dd81615396cb0a2e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1544227/000119312523169021/0001193125-23-169021-index.htm"},{"fact_type":"shareholder_vote","fact_key":"231827abf453ec2ba59e0677bbe41e8e0a3f058c","cik":1544227,"ticker":"TPST","company_name":"Tempest Therapeutics, Inc.","filed_at":"2023-06-16T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-06-15","outcome":"passed","proposal_text":"Election of Class II directors","proposal_type":"director_election","results":[{"broker_non_votes":"1,352,424","subject":"Thomas Dubensky","votes_abstain":null,"votes_against":null,"votes_for":"7,386,132","votes_withheld":"163,697"},{"broker_non_votes":"1,352,424","subject":"Christine Pellizzari","votes_abstain":null,"votes_against":null,"votes_for":"7,070,964","votes_withheld":"478,865"}]},"claim":"Tempest Therapeutics, Inc. shareholders approved Election of Class II directors at the 2023-06-15 meeting.","evidence_excerpt":"The Company’s stockholders elected the persons listed below as a Class II directors, to serve until the Company’s 2026 Annual Meeting of Stockholders or until their successors are duly elected and qualified or until their earlier death, resignation or removal.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-23-169021","anchor_url":"https://secwatch.observer/filing/0001193125-23-169021#claim-231827abf453ec2ba59e0677bbe41e8e0a3f058c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1544227/000119312523169021/0001193125-23-169021-index.htm"},{"fact_type":"earnings_release","fact_key":"303c11dabd6fada37a1120ae4f5d2adf71b9c53a","cik":1544227,"ticker":"TPST","company_name":"Tempest Therapeutics, Inc.","filed_at":"2023-05-10T23:59:59+00:00","payload":{"eps_text":"$0.55","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"Net loss and net loss per share for the quarter ended March 31, 2023 were $7.6 million and $0.55, respectively","period_text":"quarter ended March 31, 2023","report_date":"2023-05-10","result_type":"reported_results","revenue_text":null},"claim":"Tempest Therapeutics, Inc. reported quarter ended March 31, 2023 results: net income Net loss and net loss per share for the quarter ended March 31, 2023 were $7.6 million and $0.55, respectively, EPS $0.55.","evidence_excerpt":"Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class i therapeutics that combine both targeted and immune-mediated mechanisms, today reported financial results for the quarter ended March 31, 2023","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-23-020569","anchor_url":"https://secwatch.observer/filing/0000950170-23-020569#claim-303c11dabd6fada37a1120ae4f5d2adf71b9c53a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1544227/000095017023020569/0000950170-23-020569-index.htm"},{"fact_type":"earnings_release","fact_key":"d5eb9136d8389a024a8f29771494865d2315b72c","cik":1544227,"ticker":"TPST","company_name":"Tempest Therapeutics, Inc.","filed_at":"2023-03-22T23:59:59+00:00","payload":{"eps_text":"$3.09","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$35.7 million","period_text":"the year ended December 31, 2022","report_date":"2023-03-22","result_type":"reported_results","revenue_text":null},"claim":"Tempest Therapeutics, Inc. reported the year ended December 31, 2022 results: net income $35.7 million, EPS $3.09.","evidence_excerpt":"Net loss and net loss per share for the year were $35.7 million and $3.09, respectively, compared to $28.3 million and $7.47, respectively, for the same period in 2021.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0000950170-23-009236","anchor_url":"https://secwatch.observer/filing/0000950170-23-009236#claim-d5eb9136d8389a024a8f29771494865d2315b72c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1544227/000095017023009236/0000950170-23-009236-index.htm"},{"fact_type":"material_agreement","fact_key":"cc3d2a1a117526f743af329d0c965f50a0008065","cik":1544227,"ticker":"TPST","company_name":"Tempest Therapeutics, Inc.","filed_at":"2022-12-29T23:59:59+00:00","payload":{"action":"amendment","agreement_name":"First Amendment to Loan and Security Agreement","agreement_type":"credit_facility","counterparty":"Oxford Finance LLC, as collateral agent, and certain additional lenders","effective_date":"2022-12-23","item_codes_triggered":["1.01"],"value_text":"$5.0 million"},"claim":"Tempest Therapeutics, Inc. amended First Amendment to Loan and Security Agreement with Oxford Finance LLC, as collateral agent, and certain additional lenders valued at $5.0 million (effective 2022-12-23).","evidence_excerpt":"On December 23, 2022, Tempest Therapeutics, Inc. (the “ Company ”) entered into a First Amendment to Loan and Security Agreement (the “ LSA Amendment ”), which modified that certain Loan and Security Agreement dated as of January 15, 2021 (as amended, restated, supplemented or otherwise modified from time to time, the “ Loan Agreement ”) by and among TempestTX, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“ TempestTX ”), Oxford Finance LLC (the “ Lender ”), as collateral agent, and certain additional lenders party thereto from time to time. Pursuant to the LSA Amendment, (i) each of the Company and Millendo Therapeutics US, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“ Millendo ”), were joined as co-borrowers under the Loan Agreement, (ii) the interest-only repayment period was extended through December 31, 2023 (which interest-only period may be further extended through June 30, 2024 under certain circumstances), and (iii) a sec","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-22-314745","anchor_url":"https://secwatch.observer/filing/0001193125-22-314745#claim-cc3d2a1a117526f743af329d0c965f50a0008065","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1544227/000119312522314745/0001193125-22-314745-index.htm"},{"fact_type":"earnings_release","fact_key":"44b30594d1be2c4535a8bd490045ba6aa8fe7500","cik":1544227,"ticker":"TPST","company_name":"Tempest Therapeutics, Inc.","filed_at":"2022-11-08T23:59:59+00:00","payload":{"eps_text":"$0.66","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$8.9 million","period_text":"the third fiscal quarter ended September 30, 2022","report_date":"2022-11-08","result_type":"reported_results","revenue_text":null},"claim":"Tempest Therapeutics, Inc. reported the third fiscal quarter ended September 30, 2022 results: net income $8.9 million, EPS $0.66.","evidence_excerpt":"Net loss and net loss per share for the third quarter of 2022 were $8.9 million and $0.66, respectively","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001544227-22-000004","anchor_url":"https://secwatch.observer/filing/0001544227-22-000004#claim-44b30594d1be2c4535a8bd490045ba6aa8fe7500","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1544227/000154422722000004/0001544227-22-000004-index.htm"},{"fact_type":"executive_change","fact_key":"8e19f38f05","cik":1544227,"ticker":"TPST","company_name":"Tempest Therapeutics, Inc.","filed_at":"2022-09-23T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2022-09-30","interim":false,"role":"Secretary","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Nicholas Maestas was appointed as Secretary at Tempest Therapeutics, Inc..","evidence_excerpt":"The Board also appointed Nicholas Maestas, the Company’s Vice President, Strategy and Finance, as the Company’s Secretary, effective September 30, 2022.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-22-250135","anchor_url":"https://secwatch.observer/filing/0001193125-22-250135#claim-8e19f38f05","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1544227/000119312522250135/0001193125-22-250135-index.htm"},{"fact_type":"executive_change","fact_key":"f1a37afc0c","cik":1544227,"ticker":"TPST","company_name":"Tempest Therapeutics, Inc.","filed_at":"2022-09-23T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2022-09-30","interim":false,"role":"Corporate Controller, Treasurer and Principal Accounting Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Justin Trojanowski was appointed as Corporate Controller, Treasurer and Principal Accounting Officer at Tempest Therapeutics, Inc..","evidence_excerpt":"On September 21, 2022, the Board approved the promotion and appointment of Justin Trojanowski, as the Company’s Corporate Controller, Treasurer and Principal Accounting Officer, effective September 30, 2022.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-22-250135","anchor_url":"https://secwatch.observer/filing/0001193125-22-250135#claim-f1a37afc0c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1544227/000119312522250135/0001193125-22-250135-index.htm"},{"fact_type":"executive_change","fact_key":"131a48e4a7","cik":1544227,"ticker":"TPST","company_name":"Tempest Therapeutics, Inc.","filed_at":"2022-09-23T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2022-09-30","interim":false,"role":"Corporate Controller, Treasurer, Principal Accounting Officer and Secretary","role_category":"other_named_officer","successor_name":"Justin Trojanowski (Corporate Controller, Treasurer, Principal Accounting Officer) and Nicholas Maestas (Secretary)","successor_named":true},"claim":"Pierre Lorenzo resigned as Corporate Controller, Treasurer, Principal Accounting Officer and Secretary at Tempest Therapeutics, Inc..","evidence_excerpt":"On September 19, 2022, Pierre Lorenzo notified the board of directors (the “Board”) of Tempest Therapeutics, Inc. (the “Company”) of his decision to resign as the Company’s Corporate Controller, Treasurer, Principal Accounting Officer and Secretary, effective September 30, 2022.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-22-250135","anchor_url":"https://secwatch.observer/filing/0001193125-22-250135#claim-131a48e4a7","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1544227/000119312522250135/0001193125-22-250135-index.htm"},{"fact_type":"executive_change","fact_key":"5874c88609","cik":1544227,"ticker":"TPST","company_name":"Tempest Therapeutics, Inc.","filed_at":"2021-12-23T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2022-01-05","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Stella Xu resigned as Director at Tempest Therapeutics, Inc..","evidence_excerpt":"On December 20, 2021, Stella Xu notified the board of directors (the “Board”) of Tempest Therapeutics, Inc. (the “Company”) of her decision to resign as a member of the Board, effective January 5, 2022.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001628280-21-025555","anchor_url":"https://secwatch.observer/filing/0001628280-21-025555#claim-5874c88609","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1544227/000162828021025555/0001628280-21-025555-index.htm"},{"fact_type":"executive_change","fact_key":"ddfbd143fa","cik":1544227,"ticker":"TPST","company_name":"Tempest Therapeutics, Inc.","filed_at":"2021-09-30T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2021-07-12","interim":false,"role":"vice president, strategy and finance and principal financial officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Nicholas Maestas was appointed as vice president, strategy and finance and principal financial officer at Tempest Therapeutics, Inc..","evidence_excerpt":"On July 12, 2021, Nicholas Maestas, age 41, joined the Company as vice president, strategy and finance and is the Company’s principal financial officer.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001193125-21-287569","anchor_url":"https://secwatch.observer/filing/0001193125-21-287569#claim-ddfbd143fa","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1544227/000119312521287569/0001193125-21-287569-index.htm"},{"fact_type":"executive_change","fact_key":"31113f6221","cik":1544227,"ticker":"TPST","company_name":"Tempest Therapeutics, Inc.","filed_at":"2021-08-12T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2021-08-06","interim":false,"role":"Class III director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Ronit Simantov was appointed as Class III director at Tempest Therapeutics, Inc..","evidence_excerpt":"Effective as of August 6, 2021, the Company’s Board of Directors (the “Board”) appointed Ronit Simantov, M.D. to serve as Class III director of the Board.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001193125-21-244725","anchor_url":"https://secwatch.observer/filing/0001193125-21-244725#claim-31113f6221","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1544227/000119312521244725/0001193125-21-244725-index.htm"},{"fact_type":"executive_change","fact_key":"a04b7d8e22","cik":1544227,"ticker":"TPST","company_name":"Tempest Therapeutics, Inc.","filed_at":"2021-07-12T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2021-07-12","interim":false,"role":"vice president, strategy and finance and principal financial officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Nicholas Maestas was appointed as vice president, strategy and finance and principal financial officer at Tempest Therapeutics, Inc..","evidence_excerpt":"On July 12, 2021, Nicholas Maestas, age 41, joined Tempest Therapeutics, Inc. (the “Company”) as vice president, strategy and finance and is the Company’s principal financial officer.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-21-212534","anchor_url":"https://secwatch.observer/filing/0001193125-21-212534#claim-a04b7d8e22","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1544227/000119312521212534/0001193125-21-212534-index.htm"},{"fact_type":"executive_change","fact_key":"5437d1e5f7","cik":1544227,"ticker":"TPST","company_name":"Tempest Therapeutics, Inc.","filed_at":"2021-07-07T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2021-07-01","interim":false,"role":"Class II Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Christine Pellizzari was appointed as Class II Director at Tempest Therapeutics, Inc..","evidence_excerpt":"On July 1, 2021, the Board appointed Christine Pellizzari as a Class II Director.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001193125-21-209988","anchor_url":"https://secwatch.observer/filing/0001193125-21-209988#claim-5437d1e5f7","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1544227/000119312521209988/0001193125-21-209988-index.htm"}]}